American Shared Hospital Services is a 40-year-old, single-digit-million-market-cap owner and operator of stereotactic radiosurgery and radiation therapy equipment that printed a 19% revenue jump in the second quarter of 2026 while simultaneously running out of time on its only senior credit facility, a binding event combination that places the equity in a classic restructured-credit-with-positive-operating-momentum posture. The Q2 print on August 13, 2026 showed revenue of $8.4 million, up from $7.1 million in Q2 2025, driven almost entirely by the Direct Patient Services segment in Rhode Island, Peru, and Mexico, with consolidated Adjusted EBITDA of $1.34 million against $1.70 million a year ago, and a small GAAP net loss attributable to AMS of $0.07 per diluted share.
The trade, in our view, is not a recovery story about the operating business, which is performing exactly as the strategy implies, but a credit story about the next thirteen months. The Fifth Third credit agreement matured unpaid on April 9, 2026, the company entered into a Third Amendment and Forbearance Agreement on July 22, 2026 that extends the maturity to June 30, 2027 and freezes the financial covenants during the standstill period, and the company pulled a $2.0 million subordinated promissory note at 10% from an entity controlled by Executive Chairman Ray Stachowiak to backstop liquidity. The going-concern qualification is alive in the filing, the disclosure controls are not effective due to a material weakness, and the Chief Financial Officer resigned three weeks before the filing. Against that, the operating business generated $4.4 million of cash from operations in the first half of 2026, the equipment base is intact, the international Gamma Knife franchise is in its strongest comparative quarter on record, and the Rhode Island billing integration appears to be self-correcting.
The single load-bearing risk is that the company is contractually required, under the Third Amendment, to pursue a sale of all or a portion of the company or its assets during the standstill period and to hit defined milestones, with default fees payable to Fifth Third if those milestones are missed. The standalone equity value at $1.55 per share and 6.625 million shares outstanding is roughly $10.3 million, against $16.2 million of current debt and $6.8 million of cash; the enterprise value is therefore on the order of $19 to $20 million, well below the unfunded equipment commitments of $7.9 million and the $10.9 million of scheduled interest and principal over the next twelve months. The single falsifiable data point is the Q3 2026 print in early November, which reveals whether Direct Patient Services growth of 40% year over year is sustaining into the back half and whether management can credibly execute a sale process before the June 30, 2027 maturity cliff.